<DOC>
	<DOCNO>NCT00203359</DOCNO>
	<brief_summary>It widely believe inflammation contributes pathogenesis AD . TNF implicate AD neurological inflammation . Anti-TNF therapy therefore surmise potential benefit treat AD .</brief_summary>
	<brief_title>TNF-Alpha Inhibition Treatment Alzheimer 's Disease</brief_title>
	<detailed_description>Etanercept , biologic anti-TNF fusion protein , administer weekly biweekly perispinal injection maximum 15 study subject period one month , follow 5 month 6 month possible study extension , serial test cognition function monthly .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>NINCDSADRDA Criteria Alzheimer â€™ disease CT MRI consistent AD active infection CHF demyelinate disease uncontrolled diabetes mellitus vascular dementia clinically significant neurologic disease AD Hachinski &gt; 4 history lymphoma TBC wbc &lt; 2500 platelet &lt; 100,000 HCT &lt; 30 pregnancy premenopausal , fertile acceptable birth control change neuroactive medication within 4 week study initiation</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2006</verification_date>
</DOC>